308 results
8-K
EX-99.1
BIIB
Biogen Inc
24 Apr 24
First quarter revenue $2.3 billion; GAAP diluted EPS $2.70; Non-GAAP diluted EPS $3.67
7:02am
with patient identification and access progressing in the U.S. and E.U. launch now successfully underway
ZURZUVAE launch shows encouraging early trends … in properties; risks relating to access to capital and credit markets; risks related to indebtedness; the market, interest, and credit risks associated
8-K
EX-99.1
i53oosqcanskd
13 Feb 24
Biogen reports fourth quarter and full year 2023 results and expects return to Non-GAAP EPS growth in 2024
7:07am
8-K
EX-3.2
hb6rvf vy125bd
12 Dec 23
Amendments to Articles of Incorporation or Bylaws
4:36pm
8-K
EX-3.1
n4znp s60tpc136qv9x
12 Dec 23
Amendments to Articles of Incorporation or Bylaws
4:36pm
8-K
EX-99.1
k1n h88ku0ii6qtr104p
8 Nov 23
Biogen reports third quarter 2023 results and updates full year 2023 guidance
7:02am
8-K
uw392d5pm5o4mxy
26 Sep 23
Biogen Completes Acquisition of Reata Pharmaceuticals
5:25pm
8-K
EX-99.1
sqhtlw3ky wrlew
26 Sep 23
Biogen Completes Acquisition of Reata Pharmaceuticals
5:25pm
8-K
EX-10.1
k8fyvpigszzmbe5ibl
1 Sep 23
Entry into a Material Definitive Agreement
4:36pm
DEFA14A
ghmzrhjca4pf6ob 2m
31 Jul 23
Additional proxy soliciting materials
7:02am
8-K
EX-2.1
v7fhkwe
31 Jul 23
Entry into a Material Definitive Agreement
7:00am
8-K
EX-3.1
8o5xss8lo565c
31 Jul 23
Entry into a Material Definitive Agreement
7:00am
8-K
lnvkj8a0dl3z0flgoj
31 Jul 23
Entry into a Material Definitive Agreement
7:00am
DEFA14A
rhw7lbdm
28 Jul 23
Additional proxy soliciting materials
7:13am
8-K
wxghsat9 7il
28 Jul 23
Other Events
7:11am